- Home
- LFCR vs LXEO Comparison
LFCR vs LXEO Comparison
Compare LFCR & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFCR
- LXEO
- Stock Information
- Founded
- LFCR 1986
- LXEO 2017
- Country
- LFCR United States
- LXEO United States
- Employees
- LFCR N/A
- LXEO N/A
- Industry
- LFCR Biotechnology: Pharmaceutical Preparations
- LXEO
- Sector
- LFCR Health Care
- LXEO
- Exchange
- LFCR Nasdaq
- LXEO Nasdaq
- Market Cap
- LFCR 224.6M
- LXEO 140.6M
- IPO Year
- LFCR N/A
- LXEO 2023
- Fundamental
- Price
- LFCR $6.55
- LXEO $2.85
- Analyst Decision
- LFCR Buy
- LXEO Strong Buy
- Analyst Count
- LFCR 3
- LXEO 5
- Target Price
- LFCR $8.00
- LXEO $23.80
- AVG Volume (30 Days)
- LFCR 128.0K
- LXEO 497.8K
- Earning Date
- LFCR 01-02-2025
- LXEO 03-18-2025
- Dividend Yield
- LFCR N/A
- LXEO N/A
- EPS Growth
- LFCR N/A
- LXEO N/A
- EPS
- LFCR N/A
- LXEO N/A
- Revenue
- LFCR $130,858,000.00
- LXEO N/A
- Revenue This Year
- LFCR $2.24
- LXEO N/A
- Revenue Next Year
- LFCR $7.88
- LXEO N/A
- P/E Ratio
- LFCR N/A
- LXEO N/A
- Revenue Growth
- LFCR 16.47
- LXEO N/A
- 52 Week Low
- LFCR $3.68
- LXEO $2.32
- 52 Week High
- LFCR $8.00
- LXEO $19.50
- Technical
- Relative Strength Index (RSI)
- LFCR 61.32
- LXEO 37.12
- Support Level
- LFCR $6.00
- LXEO $2.51
- Resistance Level
- LFCR $6.58
- LXEO $2.95
- Average True Range (ATR)
- LFCR 0.28
- LXEO 0.33
- MACD
- LFCR 0.10
- LXEO 0.07
- Stochastic Oscillator
- LFCR 88.24
- LXEO 39.62
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.